Indian Regulator Tightens Drug Price-Control Loopholes
This article was originally published in PharmAsia News
India's drug-pricing authority warns pharmaceutical companies they need approval before they can introduce new drugs containing ingredients that are under price controls. The National Pharmaceutical Pricing Authority changed its guidelines to tighten controls on companies using loopholes to avoid price controls. The new guidelines are intended to crack down on repeat offenders, so the second move to avoid price controls is to result in automatic prosecution, instead of waiting for several rounds of hearings and other moves before action is taken. (Click here for more
You may also be interested in...
Results of three-year study conducted at 17 Canadian sites suggest that e-cigarettes use combined with counseling significantly increased abstinence from smoking cigarettes compared to receiving counseling alone.
Cambridge Nutraceuticals - which develops dietary supplements that have “proven clinical benefits” - has snapped up UK-based Prime Fifty to enhance its offering with products specifically designed for the over 50s.
Shanghai Henlius Biotech has begun dosing in a Phase I trial for its HLX14 planned biosimilar version of denosumab. Multiple biosimilar developers are vying to take a slice of the market for rivals to Amgen’s Xgeva/Prolia original.